Theravance Biopharma ( (TBPH) ) has released its Q2 earnings. Here is a breakdown of the information Theravance Biopharma presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory and neurological therapies, with a notable emphasis on its FDA-approved YUPELRI® for COPD and investigational drug ampreloxetine for neurogenic orthostatic hypotension in MSA patients.